News

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Oct 10, 2024
Read more

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

Oct 03, 2024
Read more

Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial

Sep 16, 2024
Read more

Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 13, 2024
Read more

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Sep 11, 2024
Read more

Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting

Jul 26, 2024
Read more

Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares

Jul 24, 2024
Read more

Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives

Jul 22, 2024
Read more

Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Jun 27, 2024
Read more

Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Jun 25, 2024
Read more

Allarity Therapeutics Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement

May 20, 2024
Read more

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

May 14, 2024
Read more

Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock

May 07, 2024
Read more

Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1

May 06, 2024
Read more

Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer

May 02, 2024
Read more

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Apr 29, 2024
Read more

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Apr 17, 2024
Read more

Allarity Therapeutics Announces 1-for-20 Reverse Stock Split

Apr 04, 2024
Read more

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Mar 27, 2024
Read more

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Mar 25, 2024
Read more

Quick Links

SEC Filings

IR Contact

[email protected]

Investor Email Alerts

Pipeline
Overview
– Stenoparib– External Programs
– Clinical Trials

Technology
 The DRP® Platform
Scientific Publications
About Us
Overview
Leadership
Board of Directors
SAB
Partnering
Investors
Overview
News 
Stock Info
Financials
Governance Resources
Presentations
Newsroom
 News
Media Contact

Contact
General Inquires

Careers
Join Allarity

Copyright © 2024 Allarity Therapeutics, Inc. All Rights Reserved.

Unless otherwise specified, all product and service name appearing in this internet site are trademark owned by or licensed to Allarity, its subsidiaries or affiliates. No use of any Allarity trademark, trade name, or trade dress in this site may be made without the prior written authorization of Allarity, except to identify the product or services of company.

Terms of Use 

Privacy Policy

Social Media Policy

Cookie Policy

United States:
24 School Street, 2nd Floor,
Boston, MA 02108
USA
Tel. +1 401-426-4664

Denmark:
Venlighedsvej 1
2970 Hoersholm
Denmark
Tel. +45 88 74 24 14
CVR: 34623562